News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,093 Results
Type
Article (13951)
Company Profile (304)
Press Release (247838)
Section
Business (79485)
Career Advice (151)
Deals (13210)
Drug Delivery (34)
Drug Development (50329)
Employer Resources (31)
FDA (5707)
Job Trends (5123)
News (144337)
Policy (10045)
Tag
Academia (901)
Alliances (21536)
Alzheimer's disease (756)
Approvals (5686)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4528)
Biotechnology (249)
Breast cancer (109)
Cancer (888)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40137)
Collaboration (308)
Compensation (128)
COVID-19 (1007)
C-suite (78)
Cystic fibrosis (66)
Data (983)
Diabetes (85)
Diagnostics (1209)
Drug discovery (56)
Earnings (29083)
Events (47248)
Executive appointments (247)
FDA (6073)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (310)
Government (1068)
Healthcare (6547)
Infectious disease (1044)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (860)
Job search strategy (127)
Layoffs (188)
Legal (1397)
Lung cancer (130)
Lymphoma (62)
Manufacturing (86)
Medical device (2565)
Medtech (2566)
Mergers & acquisitions (6148)
Metabolic disorders (257)
Neuroscience (999)
NextGen Class of 2024 (2005)
Non-profit (847)
Northern California (1091)
Obesity (140)
Opinion (91)
Parkinson's disease (75)
Patents (61)
People (25138)
Phase I (14150)
Phase II (18664)
Phase III (11818)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (201)
Real estate (1411)
Regulatory (8284)
Research institute (932)
Southern California (976)
Startups (1965)
United States (8656)
Vaccines (164)
Weight loss (83)
Date
Today (23)
Last 7 days (364)
Last 30 days (1469)
Last 365 days (20552)
2024 (20442)
2023 (22416)
2022 (26842)
2021 (27823)
2020 (23371)
2019 (16242)
2018 (11749)
2017 (13760)
2016 (11861)
2015 (14376)
2014 (10419)
2013 (7506)
2012 (7567)
2011 (7647)
2010 (7455)
Location
Africa (146)
Asia (17060)
Australia (2857)
California (2474)
Canada (809)
China (203)
Colorado (91)
Connecticut (103)
Europe (36453)
Florida (271)
Georgia (71)
Illinois (153)
Indiana (61)
Kansas (55)
Maryland (330)
Massachusetts (1956)
Minnesota (101)
New Jersey (630)
New York (682)
North Carolina (419)
Northern California (1091)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (278)
Washington State (247)
262,093 Results for "candel therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Prostate cancer
Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data
Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a basis for a regulatory application.
December 12, 2024
·
3 min read
·
Tristan Manalac
Press Releases
Candel Therapeutics Announces Pricing of Public Offering
December 13, 2024
·
5 min read
Press Releases
Candel Therapeutics Announces $80 Million Proposed Public Offering
December 13, 2024
·
5 min read
Genetown
Candel Therapeutics to Present at the 2024 Jefferies Global Healthcare Conference
Candel Therapeutics, Inc. announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m. ET.
May 22, 2024
·
4 min read
Press Releases
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 17, 2024
·
4 min read
Press Releases
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
November 7, 2024
·
4 min read
Genetown
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL) today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 3:00 p.m. ET.
June 18, 2024
·
5 min read
Press Releases
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024
·
11 min read
Genetown
Candel Therapeutics to Join Russell 3000® Index - June 11, 2024
Candel Therapeutics, Inc. announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
June 11, 2024
·
6 min read
FDA
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Candel Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.
April 11, 2024
·
9 min read
1 of 26,210
Next
